Development of a high-throughput formulation screening platform for monoclonal antibodies

BioProcess International

Volumn 13, Issue 8, 2015, Pages

  Casaz, Paul ^a   Brousseau, Anna ^a   Ozturk, Sadettin ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; AMMONIUM ACETATE; AMMONIUM SULFATE; CITRATE SODIUM; DODECYL SULFATE SODIUM; HISTIDINE; IMIDAZOLE; IMMUNOGLOBULIN G1 ANTIBODY; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; SUCCINIC ACID;

ACIDITY; ALKALINITY; ANIMAL CELL; ANTIBODY SCREENING; ARTICLE; BINDING ASSAY; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG MONITORING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; EVAPORATION; FOOD AND DRUG ADMINISTRATION; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHOBICITY; INCUBATION TEMPERATURE; INCUBATION TIME; LIGHT EXPOSURE; NONHUMAN; PRECIPITATION; PROTEIN AGGREGATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIZE EXCLUSION CHROMATOGRAPHY; SPECTROPHOTOMETRY; THERMOSTABILITY;

EID: 84946593929     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (33)

1. Liu H, et al. Heterogeneity of Monoclonal Antibodies. J. Pharm. Sci. 97(7) 2008: 2426-2447.
2. Davies MJ. The Oxidative Environment and Protein Damage. Biochim. Biophys. Acta. 1703(2) 2005: 93-109.
3. Yan B, et al. Analysis of Post-Translational Modifications in Recombinant Monoclonal Antibody IgG1 By Reversed-Phase Liquid Chromatography/Mass Spectrometry. J. Chromatogr. A 1164(1-2) 2007: 153-161.
4. Luo Q, et al. Chemical Modifications in Therapeutic Protein Aggregates Generated Under Different Stress Conditions. J. Biol. Chem. 286(28) 2011: 25134-25144.
5. Haberger M, et al. Assessment of Chemical Modifications of Sites in the CDRs of Recombinant Antibodies: Susceptibility vs. Functionality of Critical Quality Attributes. MAbs 6(2) 2014: 327-339.
6. Yan B, et al. Succinimide Formation at Asn 55 in the Complementarity Determining Region of a Recombinant Monoclonal Antibody IgG1 Heavy Chain. J. Pharm. Sci. 98(10) 2009: 3509-3521.
7. Brummitt RK, Nesta DP, Roberts CJ. Predicting Accelerated Aggregation Rates for Monoclonal Antibody Formulations, and Challenges for Low-Temperature Predictions. J. Pharm. Sci. 100(10) 2011: 4234-4243.
8. Joubert MK, et al. Highly Aggregated Antibody Therapeutics Can Enhance the In Vitro Innate and Late-Stage T-Cell Immune Responses. J. Biol. Chem. 287(30) 2011: 25266-25279.
9. Rombach-Riegraf V, et al. Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro. PLoS One 9(1) 2014: e86322.
10. Lewus RA, et al. Interactions and Phase Behavior of a Monoclonal Antibody. Biotechnol. Progr. 27(1) 2011: 280-289.
11. Lewus RA, et al. A Comparative Study of Monoclonal Antibodies. 1: Phase Behavior and Protein-Protein Interactions. Biotechnol. Progr. 31(1) 2015: 268-276.
12. Liu J, et al. Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 94(9) 2005: 1928-1940.
13. Mason BD, et al. Opalescence of an IgG2 Monoclonal Antibody Solution As It Relates to Liquid-Liquid Phase Separation. J. Pharm. Sci. 100(11) 2011: 4587-4596.
14. Salinas BA, et al. Understanding and Modulating Opalescence and Viscosity in a Monoclonal Antibody Formulation. J. Pharm. Sci. 99(1) 2010: 82-93.
15. Sule SV, et al. High-Throughput Analysis of Concentration-Dependent Antibody Self-Association. Biophys. J. 101(7) 2011: 1749-1757.
16. Trilisky E, et al. Crystallization and Liquid-Liquid Phase Separation of Monoclonal Antibodies and Fc-Fusion Proteins: Screening Results. Biotechnol. Progr. 27(4) 2011: 1054-1067.
17. Wang Y, et al. Quantitative Evaluation of Colloidal Stability of Antibody Solutions Using PEG-Induced Liquid-Liquid Phase Separation. Mol. Pharm. 11(5) 2014: 1391-1402.
18. Wang Y, et al. Phase Separation in Solutions of Monoclonal Antibodies and the Effect of Human Serum Albumin. Proc. Natl. Acad. Sci. USA 108(40) 2010: 16606-16611.
19. Wang W, et al. Antibody Structure, Instability, and Formulation. J. Pharm. Sci. 96(1) 2007: 1-26.
20. Capelle MA, Gurny R, Arvinte T. High Throughput Screening of Protein Formulation Stability: Practical Considerations. Eur. J. Pharm. Biopharm. 65(2) 2007: 131-148.
21. Senisterra GA, Finerty PJ Jr. High Throughput Methods of Assessing Protein Stability and Aggregation. Molec. Biosyst. 5(3) 2009: 217-523.
22. He F, et al. High Throughput Thermostability Screening of Monoclonal Antibody Formulations. J. Pharm. Sci. 99(4) 2010: 1707-1720.
23. Phillips K, de la Pena AH. Chapter 10: The Combined Use of the Thermofluor Assay and ThermoQ Analytical Software for the Determination of Protein Stability and Buffer Optimization As an Aid in Protein Crystallization. Current Protocols in Molecular Biology. Ausubel FM, et al., Eds. John Wiley and Sons: Hoboken, NJ, 1995.
24. Gibson TJ, et al. Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility During Formulation Development with IgG1 Monoclonal Antibodies. J. Pharm. Sci. 100(3) 2011: 1009-1021.
25. Kramer RM, et al. Toward a Molecular Understanding of Protein Solubility: Increased Negative Surface Charge Correlates with Increased Solubility. Biophys. J. 102(8) 2012: 1907-1915.
26. Trevino SR, Scholtz JM, Pace CN. Measuring and Increasing Protein Solubility. J. Pharm. Sci. 97(10) 2008: 4155-4166.
27. Banks DD, et al. Native-State Solubility and Transfer Free Energy As Predictive Tools for Selecting Excipients to Include in Protein Formulation Development Studies. J. Pharm. Sci. 101(8) 2012: 2720-2732.
28. Gokarn YR, et al. Self-Buffering Antibody Formulations. J. Pharm. Sci. 97(8) 2008: 3051-3066.
29. Pantoliano MW, et al. High-Density Miniaturized Thermal Shift Assays As a General Strategy for Drug Discovery. J. Biomol. Screen 6(6) 2001: 429-440.
30. Ericsson UB, et al. Thermofluor-Based High-Throughput Stability Optimization of Proteins for Structural Studies. Analyt. Biochem. 357(2) 2006: 289-298.
31. Cardamone M, Puri NK. Spectrofluorimetric Assessment of the Surface Hydrophobicity of Proteins. Biochem. J. 282(2) 1992: 589-593.
32. Cheng W, et al. Linking the Solution Viscosity of an IgG2 Monoclonal Antibody to Its Structure As a Function of pH and Temperature. J. Pharm. Sci. 102(12) 2013: 4291-4304.
33. He F, et al. Detection of IgG Aggregation By a High Throughput Method Based on Extrinsic Fluorescence. J. Pharm. Sci. 99(6) 2010: 2598-2608.